Co-administration of cannabidiol and ketamine induces antidepressant-like effects devoid of hyperlocomotor side-effects.
Ariandra Sartim, Jade Marques, Kennia Silveira, Pedro H Gobira, Francisco S Guimarães, Gregers Wegener, Sâmia R L Joca
Neuropharmacology June 19, 2021 DOI: 10.1016/j.neuropharm.2021.108679 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Animal study Peer reviewed |
|---|---|
| Population | Male Swiss mice |
| Interventions | S-Ketamine Cannabidiol NBQX |
| Dose | S-Ketamine (2.5, 3, 5, 10, 30 mg/kg), cannabidiol (3, 10, 30 mg/kg), NBQX |
| Topics | CBD Esketamine Ketamine |
| Key points | CBD produces antidepressant-like effects via AMPA receptor activation and, when combined with S-ketamine, attenuates ketamine-induced hyperlocomotion without impairing its antidepressant effect. |
Abstract
Background: AND PURPOSE Although useful as a rapid-acting antidepressant drug, ketamine is known to induce psychotomimetic effects, which may interfere with its therapeutic use. Cannabidiol (CBD) is a non-psychostimulant compound from Cannabis sativa, which has shown promising antidepressant effects without inducing hyperlocomotion. AMPA receptor activation is involved in the antidepressant effect induced by ketamine, but its relevance for the effects of CBD is not known. Moreover, given that CBD has antipsychotic and antidepressant properties, it is unknown whether adding CBD to ketamine could potentiate the antidepressant properties of ketamine while also attenuating its psychostimulant effects. EXPERIMENTAL APPROACH S-Ketamine (2.5, 3, 5, 10, 30 mg/kg) and cannabidiol (3, 10, 30 mg/kg) were administered alone or in combination to male Swiss mice. Independent groups received NBQX (AMPA receptor antagonist) 5 min before administration of CBD or S-ketamine. The antidepressant-like effect was assessed in the forced swimming test (FST), and the open field test (OFT) evaluated the psychostimulant effect. KEY RESULTS CBD induced significant dose-dependent antidepressant effects without causing hyperlocomotion in the OFT. S-ketamine produced an antidepressant effect associated with hyperlocomotion in the higher dose. NBQX inhibited the antidepressant effect of both ketamine and CBD. Pretreatment with CBD (10 mg/kg) attenuated the ketamine-induced hyperlocomotion while preserving its antidepressant effect.
Conclusion: AND
Implications: Similar to ketamine, the antidepressant-like effect elicited by CBD involves AMPA receptor activation. Additionally, CBD prevents the hyperlocomotion induced by S-ketamine without affecting its antidepressant-like effect. Our findings suggest that CBD and ketamine's combined administration can be a promising therapeutic strategy for achieving an appropriate antidepressant effect without unwanted side-effects.
Comparable studies
Other preclinical and animal studies on CBD, most cited first.
Citations in the library
Cited by 7
- Psilocybin promotes neuroplasticity and induces rapid and sustained antidepressant-like effects in mice Journal of Psychopharmacology April 28, 2024
- Psychoactive substances 25H-NBOMe and 25H-NBOH induce antidepressant-like behavior in male rats. European Journal of Pharmacology September 15, 2023
- Lutein Exerts Antioxidant and Neuroprotective Role on Schizophrenia-Like Behaviours in Mice. International Journal of Developmental Neuroscience February 1, 2025
- Cannabidiol Mitigates Ketamine-Induced Hyperlocomotion Via Allosteric Potentiation of Ventral Tegmental Glycine Receptor α1 Signaling. Biological Psychiatry March 16, 2026
- Beyond surgery: Repurposing anesthetics for treatment of central nervous system disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry June 20, 2025
and 2 more in the library
Cites 26
- A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression Archives of General Psychiatry August 1, 2006
- mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists Science August 19, 2010
- Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex Journal of Neuroscience April 15, 1997
- Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms Pharmacological Reviews June 26, 2018
- Mechanisms of Ketamine Action as an Antidepressant Molecular Psychiatry March 13, 2018
and 21 more in the library